迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02493 迈威生物-B

开市前 08-12 09:10:13

24.020

+0.000

0.00%

最高24.020	最低24.020	成交量0.00
今开24.020	昨收24.020	日振幅0.00%
总市值107.37亿	流通市值11.32亿	总股本4.47亿
成交额0.00	换手率0.00%	流通股本4,713万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":24.02,"timestamp":1786496401213,"preClose":24.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":47130200,"shares":447000000,"eps":-2.8258226100056496,"marketStatus":"开市前","change":0,"latestTime":"08-12 09:10:13","open":24.02,"high":24.02,"low":24.02,"amount":0,"amplitude":0,"askPrice":25.44,"askSize":1000,"bidPrice":23.22,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-2.710696503672086,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":1,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":24.02,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":33.19,"timestamp":1786496992000,"preClose":33.19,"halted":0,"volume":0,"delay":0,"premium":"-37.77"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63%    CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348827113.USD","03759","LU1794554557.SGD","LU0326950275.SGD","LU0039217434.USD","BK1170","PONY","LU1720050803.USD","LU0370786039.SGD","SG9999003461.SGD","688062","LU1481107354.HKD","03032","LU0269904917.USD","LU2226246903.HKD","LU1188198961.HKD","02493","LU0348766576.USD","LU1770034418.SGD","07200","LU0048580855.USD","BK1583","LU0828237940.HKD","LU0463099449.HKD","LU0164880469.USD","LU0149721374.USD","LU2460026573.USD","002821","07300","ZLAB","BK1198","LU0348825331.USD","LU1988902786.USD","09115","LU0620787316.HKD","06951","01548","LU1303224171.USD","09088","BK1587","LU0327786744.USD","HK0000320223.HKD","LU2097828714.EUR","513600","BK1183","LU0886674414.USD","LU0266512473.USD","LU1224709979.USD","LU0082770016.USD","HK0000306685.HKD","LU0140636845.USD","LU0540923850.HKD","LU1064131342.USD","BK1191","07552","BK1169","LU0061477393.USD","LU1105468828.SGD","LU0509642566.USD","02833","HSTECH","JINFF","03115","IE0032431581.USD","LU0287142896.SGD","LU0737861699.HKD","LU0634319403.HKD","LU0828237510.HKD","LU2177674079.SGD","LU2039709279.SGD","SG9999002463.SGD","LU0181495838.USD","LU0164939612.USD","LU0345780281.USD","LU0228659784.USD","LU0431992006.USD","LU1769817096.USD","03423","82800","HSI","SG9999001093.SGD","LU0868486357.SGD","LU2097828631.EUR","LU3063872942.SGD","LU0456854461.SGD","LU2264538146.SGD","LU0278937759.USD","BK1190","BK1544","06821","02631","BK1576","LU0328353924.USD","LU0082770016.SGD","LU0244354667.USD","LU2097828474.EUR","LU2488822045.USD","LU0797268264.HKD","HK0000306701.USD","LU1242518931.SGD","HK0000320264.USD","LU2399975544.HKD","02837","LU0106252389.USD","HHImain","LU0417516902.SGD","02800","LU0345780521.USD","LU1808992512.USD","03417","LU0173614495.USD","LU0828238088.HKD","300759","BK1588","688234","LU0348767384.USD","LU0164865239.USD","LU1831875114.USD","LU2008162690.USD","01541","BK1574","BK1505","MCHmain","LU1961090484.USD","09688","LU0307460666.USD","BK1592","LU0348735423.USD","ZIJMY","LU0049853897.USD","LU0274383008.USD","BK1129","01651","02026","LU1769817179.HKD","LU0979878070.USD","03088","LU2097828805.USD","601899","LU0572944931.SGD","LU0531971595.HKD","LU0417516738.SGD","BK1141","LU0043850808.USD","LU0821914370.USD","LU1242518857.USD","LU0588546209.SGD","LU1504937902.USD","LU0329678337.USD","LU1251922891.USD","06616","07500","LU2097828557.USD","LU0918141705.HKD","LU0737861772.HKD","83115","02099","LU0348814723.USD","03419","LU0211977185.USD","LU0348816934.USD","LU0469268626.HKD","LU0329678170.USD","09067","02899","LU1282648689.USD","07226","LU1719994722.HKD","BK1161","BK1594","LU0106959298.USD","LU0096374516.USD","LU1048596156.SGD","LU0165289439.USD","03033","LU0871576103.HKD","LU0918141887.USD","LU0561508036.HKD","03037","LU0266512127.USD","SG9999004220.SGD","300408","03067","BK1109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969469","title":"迈威生物-B午前涨超13% 两款地舒单抗注射液通过巴西药监机构GMP现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969469","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969469?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:55","pubTimestamp":1786420500,"startTime":"0","endTime":"0","summary":"模拟交易客户端迈威生物-B盘中涨超13%，截至发稿，股价上涨11.38%，现报25.06港元，成交额3301.81万港元。据迈威生物官微消息，近日，公司宣布其全资子公司泰康生物已顺利通过巴西国家卫生监督局针对两款地舒单抗注射液9MW0311和9MW0321的GMP现场检查。这也是迈威生物继约旦之后再次获得PIC/S成员国药监机构颁发的GMP证书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-11/doc-inimxewp0810070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159100","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966159","title":"港股异动 | 迈威生物-B(02493.HK)涨超7% 两款地舒单抗注射液通过巴西药监机构GMP现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966159?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:49","pubTimestamp":1786416560,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616876","title":"8月7日迈威生物涨7.62%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616876?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:39","pubTimestamp":1786091959,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日迈威生物涨7.62%，收盘报30.51元，换手率6.13%，成交量14.11万手，成交额4.17亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149722085","title":"迈威生物-B发布2026年7月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149722085","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149722085?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:51","pubTimestamp":1786006272,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司于2026年8月6日披露截至2026年7月31日的证券变动月报表，报告期内公司股本结构保持稳定。公司月报显示，迈威生物-B于报告期末的法定/注册股本总额为人民币446,730,200元，与上月末持平。截至2026年7月31日，迈威生物-B H股已发行股份总数为47,130,200股，均为流通股，无库存股份；A股总计399,600,000股，其中398,407,631股已上市流通，1,192,369股为库存股份，与上月末相比均无增减变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657514805","title":"8月5日迈威生物涨5.13%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657514805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657514805?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:37","pubTimestamp":1785919059,"startTime":"0","endTime":"0","summary":"证券之星消息，8月5日迈威生物涨5.13%，收盘报28.51元，换手率4.21%，成交量9.7万手，成交额2.74亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.62亿元，最新净值1.5311，较上一交易日上涨1.17%，近一年下跌22.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500030112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656324397","title":"8月3日迈威生物跌6.52%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656324397","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656324397?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:38","pubTimestamp":1785746288,"startTime":"0","endTime":"0","summary":"证券之星消息，8月3日迈威生物跌6.52%，收盘报26.81元，换手率3.77%，成交量8.67万手，成交额2.38亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300021533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656165213","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656165213","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656165213?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:46","pubTimestamp":1785606376,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，迈威生物报收于28.68元，较上周的31.09元下跌7.75%。本周，迈威生物7月27日盘中最高价报32.64元。迈威生物当前最新总市值128.12亿元，在化学制药板块市值排名35/149，在两市A股市值排名1397/5202。公司公告汇总迈威生物自愿披露关于9MW5211注射液临床试验申请获得国家药品监督管理局批准的公告。9MW5211注射液用于原发性胆汁性胆管炎适应症的临床试验申请已获批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","02493","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187358293","title":"迈威生物-B（02493）9MW5211注射液获批开展PBC临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1187358293","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187358293?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:15","pubTimestamp":1785500127,"startTime":"0","endTime":"0","summary":"7月31日，迈威（上海）生物科技股份有限公司（股票代码：02493，以下简称“迈威生物-B”）公布，其自主研发的9MW5211注射液用于原发性胆汁性胆管炎（PBC）适应症的临床试验申请已获国家药品监督管理局（NMPA）批准。该试验的《药物临床试验批准通知书》编号为2026LP023302，NMPA于2026年5月26日受理该申请并作出同意开展临床试验的审评结论。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151666563","title":"迈威生物-B获批9MW5211原发性胆汁性胆管炎临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1151666563","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151666563?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:12","pubTimestamp":1785499943,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司7月31日在港交所披露海外监管公告称，公司已于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准其自主研发的9MW5211注射液开展用于原发性胆汁性胆管炎适应症的境内临床试验。9MW5211是一款高度特异性的清除型创新抗体，针对自身免疫性疾病中由异常免疫细胞介导的关键病理机制进行精准干预。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655352363","title":"迈威生物：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655352363","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655352363?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:49","pubTimestamp":1785491373,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于原发性胆汁性胆管炎(PBC)适应症的临床试验申请获得批准。该药物是公司自主研发的清除型创新抗体，针对自身免疫性疾病，此前已获批用于炎症性肠病、多发性硬化、1型糖尿病和白癜风等适应症。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100030273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077891","title":"7月28日迈威生物跌6.83%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077891","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654077891?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:39","pubTimestamp":1785227954,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日迈威生物跌6.83%，收盘报29.45元，换手率4.48%，成交量10.32万手，成交额3.11亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653003747","title":"7月24日迈威生物跌6.21%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653003747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653003747?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:39","pubTimestamp":1784882394,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日迈威生物跌6.21%，收盘报31.09元，换手率3.64%，成交量8.37万手，成交额2.67亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652296889","title":"7月20日迈威生物涨7.39%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652296889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652296889?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:24","pubTimestamp":1784535866,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日迈威生物涨7.39%，收盘报33.29元，换手率6.53%，成交量15.03万手，成交额4.92亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.8013，较上一交易日下跌7.07%，近一年下跌14.3%。易方达医药生物股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000808.SH","163118","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237484","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获准开展白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237484","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237484?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:35","pubTimestamp":1784396110,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，迈威生物报收于31.0元，较上周的31.87元下跌2.73%。本周，迈威生物7月16日盘中最高价报36.0元。此前，该药品用于炎症性肠病、多发性硬化和1型糖尿病适应症的临床试验申请已获国家药监局批准，其中IBD适应症还获得FDA许可。9MW5211为全球首个靶向该分子的临床阶段候选药物，临床前研究显示其在多种自身免疫疾病模型中具有显著治疗潜力，且安全性良好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145126713","title":"迈威生物-B：9MW5211注射液白癜风适应症临床试验获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1145126713","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145126713?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:13","pubTimestamp":1784117584,"startTime":"0","endTime":"0","summary":"2026年7月15日，迈威（上海）生物科技股份有限公司发布自愿性公告称，其自主研发的9MW5211注射液用于白癜风适应症的临床试验申请已获国家药品监督管理局批准。公告显示，9MW5211注射液境内生产药品注册临床试验申请编号为2026LP021512。该申请于2026年5月11日受理，经审评符合药品注册相关要求，同意开展白癜风临床试验。9MW5211是一种高度特异性的清除型创新抗体，靶向在致病性免疫细胞表面特异性表达的分子，以精确清除病理性免疫细胞、阻断免疫级联反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198929758","title":"迈威生物-B(02493)获批开展9MW5211白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198929758","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198929758?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:00","pubTimestamp":1784116834,"startTime":"0","endTime":"0","summary":"2026年7月16日，迈威（上海）生物科技股份有限公司公告，其自主研发的9MW5211注射液针对白癜风的临床试验申请获国家药品监督管理局核准签发《药物临床试验批准通知书》。根据审批结论，监管机构同意公司在境内开展9MW5211注射液用于白癜风适应症的临床试验。公告显示，9MW5211为公司自主研发的清除型创新抗体，靶向自身免疫疾病中由异常免疫细胞介导的关键病理机制。公司将按照规定及时披露项目进展信息，投资者需注意投资风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457887","title":"迈威生物：9MW5211注射液获国家药监局批准开展白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457887","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651457887?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:51","pubTimestamp":1784112680,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于白癜风适应症的临床试验申请获得批准。该药物是公司自主研发的清除型创新抗体，针对自身免疫性疾病中异常免疫细胞介导的关键病理机制进行精准干预。此前，该药物用于炎症性肠病、多发性硬化和1型糖尿病等适应症的临床试验申请已获批准。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500037751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651539944","title":"7月15日迈威生物涨7.67%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651539944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651539944?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:19","pubTimestamp":1784103544,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日迈威生物涨7.67%，收盘报35.38元，换手率8.17%，成交量18.8万手，成交额6.54亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.8276，较上一交易日上涨1.6%，近一年下跌3.97%。易方达医药生物股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","000808.SH","163118","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650115423","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2650115423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650115423?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:49","pubTimestamp":1783795748,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，迈威生物报收于31.87元，较上周的32.06元下跌0.59%。本周关注点公司公告汇总：9MW5211注射液用于1型糖尿病适应症的临床试验申请获国家药监局批准公司公告汇总：该药品此前已获批用于炎症性肠病和多发性硬化适应症的临床试验公司公告汇总：9MW5211注射液针对多种自身免疫性疾病核心病理机制，具高度特异性公司公告汇总迈威生物自愿披露关于9MW5211注射液临床试验申请获得国家药品监督管理局批准的公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK1161","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":0.1548},{"period":"1month","weight":0.0221},{"period":"3month","weight":-0.0446},{"period":"6month","weight":-0.131},{"period":"ytd","weight":-0.131}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}